Press Release - A drug currently approved for smallpox in the U.S. will undergo clinical trials to treat patients infected by the Mpox viruswho are at risk of severe complications in the Democratic ...

Investigation of the Clade la strain of the virus circulation in Central Africa shows genetic mutations indicative of ...

Scientists monitor mpox virus mutations and human-to-human transmission, impacting vaccination strategies in Africa.

Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the SIGA ...

The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

Meanwhile, COVID activity remained low amid a shift in variant proportions and RSV levels rose in 3 US regions.

A shocking viral video shows a woman washing her hair in the foam-polluted Yamuna River during Chhath Puja, raising health ...

The Frederick biotechnology company BioFactura has announced $7.8 million in new contract activations to study a treatment for a potential smallpox outbreak. The company has gotten contract option ...

Four cases of more serious strain of mpox, known as Clade 1b, have been confirmed in London after the first patient returned ...

Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included in a trial conducted and sponsored by PANTHER, under the leadership of the ...

You might think of tuberculosis (TB) as a disease of the past, similar to polio or smallpox. In fact, it is the world’s most ...

Brincidofovir is an antiviral medical countermeasure that is part of Emergent's product portfolio. There are currently no therapeutics approved by the FDA to treat patients infected by mpox virus who ...